Passage Bio Stock Discussion

$Passage Bio (PASG.US)$
PHILADELPHIA, October 24, 2024 — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the company delivered preclinical and interim clinical data as part of an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress being held October 22-25, 2024, in Rome, Italy.
Details of the oral presentation are below:
Abstract Title:...

$Passage Bio (PASG.US)$ Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31stAnnual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribut...

$Passage Bio (PASG.US)$
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Passage Bio (NASDAQ: PASG) has received positive feedback from the FDA on expanding its upliFT-D trial of PBFT02to include FTD-C9orf72 patients. The company plans to amend the ongoing Phase 1/2 global study protocol to introduce this new patient population, with dosing expected to begin in 1H 2025. This expansion is supported by compelling preclin...

$Passage Bio (PASG.US)$ exciting next few weeks ahead 💸💸

$Passage Bio (PASG.US)$ 👀 things heating 🔥 up here if  close above 1.37 we will flying ✈️ parabolic ?

$Passage Bio (PASG.US)$ Passage Bio Announced Initial Safety And Biomarker Data From Three Cohort 1 Patients In The Ongoing Global Phase 1/2 UpliFT-D Trial Of PBFT02, An Adeno-associated Virus-delivery Gene Therapy For Frontotemporal Dementia With Granulin Mutations

Gainers:
• $DBV Technologies (DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics (ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova (MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid (CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax (NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...

Gainers
- $Consolidated Communications (CNSL.US)$ +14.6%: Searchlight affirms 34.6% active holding; to evaluate the possibility of a further investment in or full acquisition.
- $Voyager Therapeutics (VYGR.US)$ +12.2%: agrees to licensing option with $Novartis AG (NVS.US)$; Voyager receives $54 million upfront.
- $Aegon Ltd (AEG.US)$ +6%: provides update on Russian and Belarusian investments following invasion of Ukraine.
- $AZZ Inc (AZZ.US)$ +...